Roth Capital weighs in on Pozen (POZN -15%) after the FDA asked drug developer to provide additional information about its potentially less gastro-erosive aspirin, saying the shares should be bought on the weakness. Roth thinks the company will still be able to file an application for the drug with the FDA by the end of the year. The firm maintains a $10 target and Buy rating on the stock.
Roth Capital weighs in on Pozen (POZN -15%) after the FDA asked drug developer to provide...
From other sites
at CNBC.com (Dec 17, 2014)
at CNBC.com (Dec 15, 2014)
at CNBC.com (Nov 18, 2014)
at CNBC.com (Nov 10, 2014)
at CNBC.com (Nov 22, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs